Bio-Techne Corporation and Catalent, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends in the Biotech Sector

In the competitive landscape of the biotech industry, understanding spending patterns is crucial. Over the past decade, Bio-Techne Corporation and Catalent, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2024, Bio-Techne's SG&A expenses have grown by approximately 550%, reflecting a strategic expansion and investment in operational capabilities. In contrast, Catalent, Inc. has seen a more modest increase of around 180% during the same period, indicating a steady yet controlled growth approach.

Key Insights

• Bio-Techne's Surge: The company saw a significant rise in SG&A expenses, particularly between 2017 and 2024, suggesting aggressive market positioning.
• Catalent's Consistency: Despite a slower growth rate, Catalent's expenses remained consistently higher, peaking in 2024, which may highlight a focus on maintaining robust operational frameworks.

These patterns offer a window into each company's strategic priorities and market positioning.